| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/BI00301A024 |
| P698 | PubMed publication ID | 6712942 |
| P2093 | author name string | M G Brattain | |
| B H Long | |||
| S T Musial | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cytotoxicity | Q246181 |
| quantitative structure-activity relationship | Q766383 | ||
| P304 | page(s) | 1183-1188 | |
| P577 | publication date | 1984-03-01 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship | |
| P478 | volume | 23 |
| Q55021320 | A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. |
| Q42804527 | Abrogation of etoposide-mediated cytotoxicity by cycloheximide |
| Q55382440 | Analysis of DNA fragmentation in human uterine cervix carcinoma HeLa S3 cells treated with duocarmycins or other antitumor agents by pulse field gel electrophoresis. |
| Q35233723 | Apoptosis induced by anticancer drugs |
| Q36466122 | Biochemical pharmacology of anthracenediones and anthrapyrazoles |
| Q24627367 | Bioflavonoids as poisons of human topoisomerase II alpha and II beta |
| Q89842982 | Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms |
| Q89993903 | Chemicals and Drugs Forming Reactive Quinone and Quinone Imine Metabolites |
| Q72708242 | Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors |
| Q41687138 | Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions |
| Q43649722 | Cytotoxic cyclolignans related to podophyllotoxin |
| Q44045668 | Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines |
| Q40853538 | DNA topoisomerase I and II in cancer chemotherapy: update and perspectives |
| Q42541938 | Discovery of podophyllotoxins |
| Q41650639 | Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids |
| Q36453763 | Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? |
| Q27000099 | Drugging topoisomerases: lessons and challenges |
| Q70388852 | Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity |
| Q37331797 | Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells |
| Q45105697 | Establishment and characterization of resistant cells to etoposide (VP16) from a mouse breast cancer cell line, FM3A. |
| Q39523026 | Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics |
| Q41332538 | Etoposide-induced DNA cleavage in human leukemia cells |
| Q67486552 | Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice |
| Q46331807 | Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells |
| Q40630925 | Hypoxia and drug resistance |
| Q92573709 | IS METABOLIC ACTIVATION OF TOPOISOMERASE II POISONS IMPORTANT IN THE MECHANISM OF CYTOTOXICITY? |
| Q41704596 | Increased levels of mitochondrial DNA in an etoposide-resistant human monocytic leukaemia cell line (THP-1/E) |
| Q41050547 | Inhibition of human topoisomerase II by anti-neoplastic benzazolo[3,2-alpha]quinolinium chlorides |
| Q70221818 | Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26 |
| Q34909651 | Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage |
| Q92533787 | Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations |
| Q45052309 | Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. |
| Q37721521 | Long-term effects of chromatin remodeling and DNA damage in stem cells induced by environmental and dietary agents |
| Q40696510 | Multilevel therapeutic targeting by topoisomerase inhibitors |
| Q37008894 | Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells |
| Q39768346 | Pharmacokinetics of anticancer drugs in children |
| Q50153881 | Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses. |
| Q91738703 | Protective potentials of Annona muricata fruit pulp on etoposide-induced gastrointestinal toxicity in Wistar rats |
| Q42859727 | Purification of a new peroxidase catalysing the formation of lignan-type compounds |
| Q27005726 | Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents |
| Q41268874 | Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance |
| Q33270072 | Reproductive death of chinese hamster V79 cells after exposure to chemical inhibitors of DNA synthesis |
| Q37394291 | Role for topoisomerases in the release of DNA into the detergent-soluble fraction of eukaryotic cells |
| Q36971716 | Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213). |
| Q41873946 | Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. |
| Q37332317 | Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. |
| Q40912299 | The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks. |
| Q39658304 | The clinical pharmacology of etoposide and teniposide |
| Q55112585 | The lignans of Podophyllum |
| Q33922870 | Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. |
| Q40499871 | Topoisomerase inhibitors. A review of their therapeutic potential in cancer |
| Q36920787 | Topoisomerase-specific drug sensitivity in relation to cell cycle progression |
| Q33875792 | Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). |
Search more.